MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.390
-0.180
-11.47%
After Hours: 1.450 +0.06 +4.32% 18:04 04/16 EDT
OPEN
1.530
PREV CLOSE
1.570
HIGH
1.540
LOW
1.380
VOLUME
406.83K
TURNOVER
--
52 WEEK HIGH
3.350
52 WEEK LOW
0.5011
MARKET CAP
42.57M
P/E (TTM)
-0.6775
1D
5D
1M
3M
1Y
5Y
Kintara glioblastoma candidate VAL-083 benefits progression-free survival
Interim data from two phase 2 trials of Kintara Therapeutics' (KTRA) glioblastoma multiforme (GBM) candidate VAL-083 showed that the drug extends progression-free survival ("PFS") compared to a standard of care.In the
Seekingalpha · 6d ago
Kintara Highlights Updates On Two Phase 2 Clinical Trials Of VAL-083 At 2021 American Association For Cancer Research Annual Meeting
 Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing, or resistant to, current
Benzinga · 6d ago
Kintara Presents Updates on Two Phase 2 Clinical Trials at the 2021 American Association for Cancer Research Annual Meeting
SAN DIEGO, April 12, 2021 /PRNewswire via COMTEX/ -- SAN DIEGO, April 12, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the...
PR Newswire - PRF · 6d ago
Kintara Taking The Lead In Developing New And Innovative Rare Cancer Therapies
Kintara Therapeutics, Inc. Chief Executive Officer Saiid Zarrabian participated in the Benzinga Biotech Small Cap Conference held March 24-25, 2021. 
Benzinga · 04/05 14:51
Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference
Exciting and insightful biotech news was front and center at the Benzinga Biotech Small Cap Conference, a two-day event that kicked off virtually Wednesday.
Benzinga · 03/25 18:45
BRIEF-Kintara Therapeutics Inc Files For Mixed Shelf Of Upto $100 Million - SEC Filing
reuters.com · 03/24 22:17
Benzinga's Biotech Small Cap Conference Schedule For Wednesday, Mar. 24, 2021
9:25 a.m. EDT - Lantern Pharma (LTRN) CEO, Panna Sharma 9:25 a.m. - AcelRx Pharma (ACRX) CEO, Vincent Angotti 9:45 a.m. - Kintara Therapeutics (KTRA) CEO, Saiid Zarrabian 9:45 a.m. - Lexaria Bioscience (LEXX) Chair,
Benzinga · 03/23 23:12
Kintara Therapeutics to Participate in Benzinga Biotech Small Cap Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that its Chief Executive Officer Saiid Zarrabian will participate in the Ben...
PR Newswire · 03/17 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTRA stock price target is 5.81 with a high estimate of 7.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 493.53K
% Owned: 1.61%
Shares Outstanding: 30.63M
TypeInstitutionsShares
Increased
4
17.04K
New
7
356.91K
Decreased
3
138.85K
Sold Out
4
46.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Robert Hoffman
President/Chief Executive Officer/Director
Saiid Zarrabian
Chief Financial Officer
Scott Praill
Chief Scientific Officer
Dennis Brown
Director
John Liatos
Director
Keith Murphy
Independent Director
Robert Toth
No Data
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.